After discovering that cells impacted by acute lymphoblastic leukemia contain an atypical DNA sequence that differs for each individual, the genetic passport initiative was put in place to find the optimal method for treating genetic anomalies at more personalized level. In spite of the fact that 85% of pediatric patients recover, it is imperative to take all preventative measures to improve the quality of life and reduce potential risks. Thanks to the genetic passport initiative, the medical team at the Tettamanti Reserch Center in Monza is measuring each patient’s initial reaction to multiple chemotherapy methods through Minimal Residual Disease (MRD). This way they can identify new subgroups of patients with an elevated risk of relapse, in order to provide alternative therapies and pharmaceuticals catered to each individual’s specific needs. The initiative seeks to provide access to these treatment methods that would otherwise be a financial difficulty for affected families.